Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report
Clinical Hematology International · 26.05.2026 · 8 (2)
DOI: 10.46989/001c.161719 ↗Kurz gefasst
Fallbericht in der Zeitschrift Clinical Hematology International, online erschienen am 26.05.2026. Verfasst von Kentaro Nagae und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic UBA1 mutations and frequently complicated by myelodysplastic syndrome (MDS). Conventional immunosuppressive and anti-inflammatory therapies are often ineffective, and allogeneic hematopoietic stem cell transplantation (allo-HSCT) is currently the only curative treatment, although its optimal timing and donor selection remain uncertain. Case Presentation A 67-year-old man with VEXAS syndrome and MDS harboring UBA1 (p.M41T) and EZH2 mutations, refractory to azacitidine and corticosteroids, successfully underwent allo-HSCT from a one-antigen–mismatched related donor. Post-transplant chronic graft-versus-host disease was well controlled with ruxolitinib. Methods and Results We reviewed eight studies comprising 45 allo-HSCT recipients with VEXAS syndrome. The median age at transplantation was 59 years, and patients had received a median of five prior systemic therapies. MDS was present in 53.3% of cases, while 42.2% underwent transplantation for VEXAS without overt hematologic malignancy. The most frequent UBA1 variant was p.Met41Val (37.8%). At last follow-up, 84.4% of patients were alive, with resolution of inflammatory manifestations in most cases.
Conclusion
Allo-HSCT represents a curative option for refractory VEXAS syndrome. Comprehensive genetic profiling may aid in identifying candidates for early transplantation. If early transplantation is required, human leukocyte antigen-mismatched donors may be selected.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Hematology/Oncology, Kurashiki Central Hospital, Kurashiki, Okayama, Japan.
- Division of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.
ORCID-Profile: Hiroyuki Muranushi
Zitieren
APA
Nagae, K., Muranushi, H., Nannya, Y., & Maeda, T. (2026). Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report. Clinical Hematology International, 8(2). https://doi.org/10.46989/001c.161719
Vancouver
Nagae K, Muranushi H, Nannya Y, Maeda T. Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report. Clinical Hematology International. 2026;8(2). doi:10.46989/001c.161719
BibTeX
@article{Nagae2026,
author = {Nagae, Kentaro and Muranushi, Hiroyuki and Nannya, Yasuhito and Maeda, Takeshi},
title = {Allogeneic hematopoietic stem cell transplantation for VEXAS syndrome: A review and a case report},
journal = {Clinical Hematology International},
year = {2026},
volume = {8},
number = {2},
doi = {10.46989/001c.161719}
}
EUVIMED